Oncolytics Biotech Earnings Call Transcripts
Fiscal Year 2026
-
The meeting approved the Continuance and Domestication Resolutions by a two-thirds majority and the 2026 Incentive Award Plan by a majority, with no questions raised on any motions. Voting procedures and shareholder participation were clearly outlined.
Fiscal Year 2025
-
The meeting confirmed quorum, approved all motions, and elected directors and auditors. Strategic focus will shift to advancing pelareorep in pancreatic cancer, with plans to extend IP and avoid dilutive capital raises until key milestones are met.
-
PELA, an IV oncolytic virus, shows strong efficacy and durable responses in metastatic pancreatic and colorectal cancers, with a favorable safety profile and broad platform potential. Experts support advancing to phase III trials and highlight its synergy with chemo and immunotherapy.
-
Strong clinical progress for pelareorep in breast, pancreatic, and anal cancers, with two phase 2 breast cancer studies showing significant survival benefits. Financial position remains stable with a $20M share purchase agreement, supporting ongoing trials and CEO transition.
Fiscal Year 2024
-
Pelareorep showed strong efficacy in breast, pancreatic, and anal cancers, with positive data supporting registration-enabling studies and potential accelerated approval. Financials reflect prudent cash management, and industry interest in oncolytic viruses is rising.
-
Final BRACELET-1 data showed pelareorep nearly doubled key survival metrics in metastatic breast cancer, supporting plans for registration-enabling studies and accelerated approval. Cash burn decreased, R&D spending rose, and strategic partnerships and grants are advancing pancreatic cancer trials.
-
Pelareorep demonstrated strong survival and progression-free survival benefits in metastatic breast cancer, with a favorable safety profile and plans for a pivotal phase 2 study targeting accelerated approval. Pancreatic and anal cancer programs are advancing, supported by grants and collaborations.
-
Pelareorep, a naturally occurring oncolytic virus, is advancing in late-stage trials for metastatic breast and pancreatic cancers, with pivotal data and regulatory submissions expected soon. The programs target significant unmet needs and leverage strong early efficacy signals.
-
Pelareorep demonstrated strong immunotherapeutic activity and positive clinical data in breast and pancreatic cancers, with registration strategies advancing for both indications. Funding is secured for current studies, but additional capital will be needed for future registration trials.
-
Advanced registration-enabling studies for Pela in breast and pancreatic cancer, secured a $5M PanCAN award, and entered a strategic collaboration with GCAR. Reported a stable net loss and cash runway into 2025, with key trial readouts expected in the second half of 2024.